Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?
Inflammation is implicated in the development and severity of the coronavirus disease 2019 (COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when uncontrolled, is also recognized as an important risk factor for COVID-19 morbidity and mortality. Furthermore, certain infl...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12859
- Acceso en línea:
- https://doi.org/10.1016/j.jdiacomp.2020.107723
http://hdl.handle.net/20.500.12010/12859
- Palabra clave:
- Metformin
Pioglitazone
Dipeptidyl peptidase 4 inhibitors
Glucagon-like peptide-1 receptor agonists
Sodium-glucose co-transporter-2 inhibitors
C-reactive protein
Interleukin 6
Ferritin
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Acceso restringido